Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab.

American journal of hematology - 1 Jun 2017

Huet Sarah, Szafer-Glusman Edith, Tesson Bruno, Xerri Luc, Fairbrother Wayne J, Mukhyala Kiran, Bolen Chris, Punnoose Elizabeth, Tonon Laurie, Chassagne-Clément Catherine, Feugier Pierre, Viari Alain, Jardin Fabrice, Salles Gilles, Sujobert Pierre

Abstract excerpt

BCL2 mutations have been suggested to confer an adverse prognosis to follicular lymphoma (FL) patients, but their prognostic value has not been assessed in patients treated with a rituximab-containing regimen. Here we evaluated the prognostic value of BCL2 mutations in a large prospective cohort of 252 patients with FL treated with immunochemotherapy in the PRIMA randomized trial. Using a DNA-targeted sequencing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Lymphoma, Follicular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Prognosis

Share to Proto-Oncogene Proteins c-bcl-2

Share to Rituximab

Share to Translocation, Genetic

Share to Treatment Outcome

Source

Identifiers

PMID: 28247997
DOI: 10.1002/ajh.24701

Genes

BCL2
AICDA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BCL2 mutations do not confer adverse prognosis in follicular lymphoma patients treated with rituximab.PMID 28247997Read ↗

Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era.Semantic proximity Read ↗

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.Semantic proximity Read ↗

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.Semantic proximity Read ↗

Distribution of BCL2 breakpoints in follicular lymphoma and correlation with clinical features: specific subtypes or same disease?Semantic proximity Read ↗

Clinical and Biological Prognostic Factors in Follicular Lymphoma.Semantic proximity Read ↗

Decreased Expression of T-Cell-Associated Immune Markers Predicts Poor Prognosis in Patients with Advanced Follicular Lymphoma Received Rituximab Plus BendamustineSemantic proximity Read ↗

Functional Implications of the spectrum of BCL2 mutations in Lymphoma.Semantic proximity Read ↗

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry.Semantic proximity Read ↗

Incidence and Clinical Significance of Bcl-2 / IgH Rearrangements in Follicular LymphomaSemantic proximity Read ↗

Tumor suppressors in follicular lymphoma.Semantic proximity Read ↗

BCL2 mutation spectrum in B-cell non-Hodgkin lymphomas and patterns associated with evolution of follicular lymphoma.Semantic proximity Read ↗

Partial lack of BCL2 in follicular lymphoma: An unusual immunohistochemical staining pattern explained by ongoing BCL2 mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.